Results 31 to 40 of about 4,757 (93)

Pharmacovigilance‐Based Identification and Mechanistic Exploration of Periodontitis‐Related Drugs

Journal of Clinical Periodontology, Volume 53, Issue 1, Page 117-126, January 2026.
ABSTRACT Background Periodontitis is a common chronic inflammatory disease. However, drug‐related risks and underlying molecular mechanisms remain underexplored from large real‐world data. Methods We first mined the US Food and Drug Administration Adverse Event Reporting System (FAERS) database to identify drugs disproportionately associated with ...
Wuda Huoshen, Junkai Xiong, Xunmi Ma, Heng Wang, Panyu Cheng, Xinyu Chen, Ge Shuai, Yi Chen, Xinyue Zhang, Chen Sun, Chunhui Li, Rui Shi   +11 more
wiley   +1 more source

Relationship Between Trimethoprim‐Sulfamethoxazole‐Induced Hepatotoxicity and Cytochrome Protein 450 2C9 Using Food and Drug Administration Adverse Event Reporting System Database

Journal of Clinical Pharmacy and Therapeutics, Volume 2026, Issue 1, 2026.
Background Trimethoprim‐sulfamethoxazole (TMP‐SMX) is the second most frequently implicated drug for liver injury. A previous study reported that its onset may be due to the activation of cytochrome protein 450 (CYP) 2C9. However, few studies have measured the expression levels of CYP2C9 in clinical settings; thus, the association between TMP‐SMX ...
Hideo Kato, Chihiro Shiraishi, Mao Hagihara, Hiroshige Mikamo, Takuya Iwamoto, Ali Imran   +5 more
wiley   +1 more source

Managing the Complex Intersection Between Substance Use Disorders and Infectious Diseases

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, Volume 9, Issue 3, March 2026.
Karissa Chow, Amanda Binkley, Jessica Meisner, Samantha Huo, Matthew Hinton   +4 more
wiley   +1 more source

In Vitro Assessment of Drug‐Induced Liver Injury Using Three‐Dimensional Cultured HepaSH Cells Derived From Chimeric Mouse Model With Humanized Liver

Journal of Applied Toxicology, Volume 45, Issue 12, Page 2641-2653, December 2025.
ABSTRACT Drug‐induced liver injury (DILI) is a serious adverse event and a common cause of postmarketing drug withdrawal. Despite nonclinical assessments of DILI risk, which are predominantly conducted in experimental animals, DILI remains a frequent adverse event, highlighting the need to improve nonclinical assessments.
Xingming Liu, Yuichiro Higuchi, Yuta Sakamoto, Shota Yanagida, Shotaro Uehara, Hiroshi Suemizu, Yasunari Kanda, Hiroyuki Kawagishi   +7 more
wiley   +1 more source

The Concise Guide to PHARMACOLOGY 2025/26: Enzymes

British Journal of Pharmacology, Volume 182, Issue S1, Page S307-S403, December 2025.
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander, Doriano Fabbro, Alasdair J. Gibb, Eamonn Kelly, Alistair A. Mathie, Chloe J. Peach, Emma L. Veale, Jane F. Armstrong, Elena Faccenda, Simon D. Harding, Christopher Southan, Jamie A. Davies, Stephanie Annett, Detlev Boison, Kathryn Elisa Burns, Carmen Dessauer, Jürg Gertsch, Nuala Ann Helsby, Angelo A. Izzo, Rennolds Ostrom, Ester Pagano, Andreas Papapetropoulos, Nigel J. Pyne, Susan Pyne, Tracy Robson, Roland Seifert, Johannes‐Peter Stasch, Csaba Szabo, Mario van der Stelt, Albert van der Vliet, Val Watts, Szu Shen Wong   +31 more
wiley   +1 more source

Derivation of a health‐based guidance value for Δ8‐tetrahydrocannabinol (Δ8‐THC) and its occurrence in food

EFSA Journal, Volume 23, Issue 11, November 2025.
Abstract The European Food Safety Authority (EFSA) was asked to deliver a scientific opinion on the derivation of a health‐based guidance value (HBGV) for Δ8‐tetrahydrocannabinol (Δ8‐THC) in food with an assessment of the occurrence of Δ8‐THC and the co‐occurrence with Δ9‐THC in hemp and hemp‐derived products.
EFSA Panel on Contaminants in the Food Chain (CONTAM), Helle Katrine Knutsen, Agneta Åkesson, Vasileios Bampidis, Margherita Bignami, James Kevin Chipman, Gisela Degen, Antonio Hernández‐Jerez, Tim Hofer, Christer Hogstrand, Stefano Landi, Jean‐Charles Leblanc, Kyriaki Machera, Evangelia Ntzani, Isabelle P. Oswald, Guido Rychen, Salomon Sand, Katharina Vejdovszky, Barbara Viviani, Birgit Dusemund, Carlo Nebbia, Stefan Weigel, Claudia Cascio, Anna Christodoulidou, José Cortiñas Abrahantes, Bruno Dujardin, Andrea Gissi, Lydia Alarcón Asensio, Eleni Gkimprixi, Tuuli Tauriainen, Laurent Bodin   +30 more
wiley   +1 more source

Risk of Hepatotoxicity in Patients With Gout Treated With Febuxostat or Benzbromarone: A Propensity Score–Matched Cohort Study

Arthritis Care &Research, Volume 77, Issue 9, Page 1149-1156, September 2025.
Objective The objective of this study was to evaluate and compare the risk of hepatotoxicity associated with the use of febuxostat and benzbromarone in patients with gout. Methods New users of febuxostat or benzbromarone with monitoring of liver function at least three times in a year after initiation of the study drugs were identified from an ...
Wenyan Sun, Lingling Cui, Robert Terkeltaub, Ying Chen, Xinde Li, Xiaoyu Cheng, Tian Liu, Nicola Dalbeth, Changgui Li   +8 more
wiley   +1 more source

Discovery of a Phenylalanine‐Derived Natural Compound as a Potential Dual Inhibitor of MDM2 and MDMX

ChemMedChem, Volume 20, Issue 16, August 16, 2025.
P5, a novel phenylalanine‐derived compound isolated from Micromonospora sp. MS‐62, exhibits dual inhibition of MDM2 and MDMX. Molecular docking and SPR confirm its nanomolar affinity and sustained binding kinetics. In silico profiling reveals high GI absorption, BBB permeability, and drug‐likeness, highlighting its potential as a lead for p53‐targeted ...
Ja Young Cho, Sanghwa Park, Taejung Kim, Junghye Eom, Jung‐Rae Rho, Hyoung‐Woo Bai   +5 more
wiley   +1 more source

Prevalence of Actionable Pharmacogenetic Genotype Frequencies, Cautionary Medication Use, and Polypharmacy in Community‐Dwelling Older Adults

Clinical Pharmacology &Therapeutics, Volume 118, Issue 2, Page 337-342, August 2025.
Older adults (65 years and over) frequently manage complex medication regimens and are vulnerable to adverse drug reactions and treatment inefficacies, some of which could be preventable with pharmacogenetics (PGx)‐guided prescribing. This study examined the prevalence of actionable PGx genotypes (i.e., those linked to a guideline that recommends a ...
Chad A. Bousman, Ankita Narang, Ziad Al Bkhetan, Robyn L. Woods, Suzanne G. Orchard, Alice J. Owen, Michelle A. Fravel, Julia Gilmartin‐Thomas, Joanne Ryan, Peter D. Fransquet, Rory Wolfe, Chenglong Yu, John J. McNeil, Paul Lacaze, Michael E. Ernst   +14 more
wiley   +1 more source

The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo

Drug Design, Development and Therapy, 2018
Dmitrij A Sychev,1 Ghulam Md Ashraf,2 Andrey A Svistunov,3 Maksim L Maksimov,4 Vadim V Tarasov,3 Vladimir N Chubarev,3 Vitalij A Otdelenov,1 Natal’ja P Denisenko,1 George E Barreto,5,6 Gjumrakch Aliev7–9 1Russian Medical Academy of ...
Sychev DA, Ashraf GM, Svistunov AA, Maksimov ML, Tarasov VV, Chubarev VN, Otdelenov VA, Denisenko NP, Barreto GE, Aliev G   +9 more
doaj